kaleab alemayehu zewdie - Toxicology

Author Information

Kaleab Alemayehu Zewdie is a researcher affiliated with the Department of Pharmacology and Toxicology at the School of Pharmacy, Mekelle University, located in Mekelle, Ethiopia. His research primarily focuses on pharmacology and toxicology, contributing to a deeper understanding of drug effects and health issues. His work is crucial in the advancement of therapeutic approaches and public health strategies.

Research Contributions

Kaleab Alemayehu Zewdie has made significant contributions to the fields of pharmacology and toxicology through his research work. His publications cover a broad spectrum of topics including the protective effects of antioxidants against nephrotoxicity, antileishmanial activity of drugs, and novel treatments for epilepsy, among others. His studies often focus on evaluating the efficacy and safety of various therapeutic agents, as well as understanding the global burden of diseases such as cirrhosis and chronic kidney disease. His work is instrumental in providing insights into disease management and therapeutic innovations.

Aliases

There are no aliases provided for Kaleab Alemayehu Zewdie, indicating that he is primarily known by his full name in academic and professional circles.

Publication and Citation Metrics

Metric	Value
Citation Count	4180
H-index	12
Paper Count	21

Publications:

Potential Protective Effects of Antioxidants against Cyclophosphamide-Induced Nephrotoxicity

DOI: 10.1155/2022/5096825

Year: 2022

Antileishmanial Activity of Tamoxifen by Targeting Sphingolipid Metabolism: A Review

DOI: 10.2147/CPAA.S344268

Year: 2022

Montelukast: The New Therapeutic Option for the Treatment of Epilepsy

DOI: 10.2147/JEP.S277720

Year: 2021

Evaluation of in-vivo antidiarrhoeal and in-vitro antibacterial activities of the root extract of Brucea antidysenterica J. F. Mill (Simaroubaceae)

DOI: 10.1186/s12906-020-03001-7

Year: 2020

Targeting Netrin-1 and -4 as a Novel Diagnostic Parameter and Treatment Option for Diabetic Retinopathy

DOI: 10.2147/OPTH.S258044

Year: 2020

The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

DOI: 10.1016/S2468-1253(19)30349-8

Year: 2020

Five insights from the Global Burden of Disease Study 2019

DOI: 10.1016/S0140-6736(20)31404-5

Year: 2020

Plasma Adipsin as a Biomarker and Its Implication in Type 2 Diabetes Mellitus

DOI: 10.2147/DMSO.S253967

Year: 2020

Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

DOI: 10.1016/S0140-6736(20)30925-9

Year: 2020

Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

DOI: 10.1016/S0140-6736(20)30045-3

Year: 2020

What are the Key Components of a Toxicology Safety Audit?

Is Sunscreen Safe?

How Are Ethical Guidelines Applied?

What is Non-Hodgkin Lymphoma?

What are the penalties for violating the CSA?

Why is Studying Polymorphic Variants Important?

What is Sustainable Development in Toxicology?

How is Toxin-Induced Ataxia Diagnosed?

Are There Regulatory Guidelines for Taxiphyllin?

What Toxic Substances Can Cause Headaches?

Partnered Content Networks

Relevant Topics